Given that the expression levels of FCGR3A and FGL2 exhibit similar trends across different subtypes of gliomas and the anatomical localization is the same in tumor, we propose that FCGR3A and FGL2 co express in gliomas. This evidence concerns the gene FGL2 and central nervous system cancer.